Clinical Trial Update: G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating G-CSF to prevent neutropenia during first-line chemotherapy with bevacizumab in metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• G-CSF (granulocyte colony-stimulating factor)

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED